CN113301961A - 给予抗tim-3抗体的方法 - Google Patents

给予抗tim-3抗体的方法 Download PDF

Info

Publication number
CN113301961A
CN113301961A CN201980086650.3A CN201980086650A CN113301961A CN 113301961 A CN113301961 A CN 113301961A CN 201980086650 A CN201980086650 A CN 201980086650A CN 113301961 A CN113301961 A CN 113301961A
Authority
CN
China
Prior art keywords
tim
antibody
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980086650.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·瑞斯
R·萨娜杰迪诺夫
章东
赵新燕
安琦
D·南那曼
V·D·苏德
C·伊夫兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN113301961A publication Critical patent/CN113301961A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980086650.3A 2018-11-01 2019-11-01 给予抗tim-3抗体的方法 Pending CN113301961A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862754378P 2018-11-01 2018-11-01
US62/754,378 2018-11-01
PCT/US2019/059556 WO2020093024A2 (en) 2018-11-01 2019-11-01 Methods of administering anti-tim-3 antibodies

Publications (1)

Publication Number Publication Date
CN113301961A true CN113301961A (zh) 2021-08-24

Family

ID=69159932

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980086650.3A Pending CN113301961A (zh) 2018-11-01 2019-11-01 给予抗tim-3抗体的方法

Country Status (8)

Country Link
US (1) US20220073616A1 (https=)
EP (1) EP3873612A2 (https=)
JP (1) JP2022505923A (https=)
CN (1) CN113301961A (https=)
AU (1) AU2019372436A1 (https=)
CA (1) CA3117371A1 (https=)
IL (1) IL282708A (https=)
WO (1) WO2020093024A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116688115A (zh) * 2022-03-18 2023-09-05 上海齐鲁制药研究中心有限公司 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
CN118255902A (zh) 2017-03-02 2024-06-28 加拿大国家研究委员会 TGF-β受体胞外域融合分子及其用途
MX2023000005A (es) * 2020-06-26 2023-03-06 Sorrento Therapeutics Inc Virus del herpes simple (vhs) oncolíticos que expresan proteínas de fusión inmunomoduladoras.
CN117120091A (zh) * 2021-04-13 2023-11-24 免疫医疗有限责任公司 靶向pd-1和tim-3的双特异性抗体
CN117377692A (zh) 2021-04-23 2024-01-09 苏州逻晟生物医药有限公司 Tim-3-靶向抗体及其用途
CN117545506A (zh) * 2021-06-24 2024-02-09 百时美施贵宝公司 用于治疗疾病的转化生长因子-β配体陷阱

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080131434A1 (en) * 2006-06-13 2008-06-05 Lewicki John A Compositions and methods for diagnosing and treating cancer
US20150218274A1 (en) * 2014-01-31 2015-08-06 Novartis Ag Antibody molecules to tim-3 and uses thereof
CN106103488A (zh) * 2014-02-10 2016-11-09 默克专利有限公司 靶向TGFβ抑制
US20170157250A1 (en) * 2014-07-11 2017-06-08 Genmab A/S Antibodies binding axl
CN107001478A (zh) * 2014-10-14 2017-08-01 诺华股份有限公司 针对pd‑l1的抗体分子及其用途
CN107207593A (zh) * 2014-12-09 2017-09-26 雷纳神经科学公司 抗pd‑1抗体及其使用方法
US20170355770A1 (en) * 2016-06-13 2017-12-14 Askgene Pharma Inc. PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
WO2018085469A2 (en) * 2016-11-01 2018-05-11 Anaptysbio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
TW201825513A (zh) * 2016-11-29 2018-07-16 美商提薩羅有限公司 針對ｔ細胞免疫球蛋白及黏蛋白３（ｔｉｍ-３）之抗體
US20180207273A1 (en) * 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
CA3083324A1 (en) 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US8841418B2 (en) * 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
CN109640988A (zh) * 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
JOP20190013A1 (ar) * 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
AU2018264455B2 (en) 2017-05-12 2024-12-12 Jiangsu Hengrui Medicine Co., Ltd. Fusion protein containing TGF-beta receptor and medicinal uses thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080131434A1 (en) * 2006-06-13 2008-06-05 Lewicki John A Compositions and methods for diagnosing and treating cancer
US20150218274A1 (en) * 2014-01-31 2015-08-06 Novartis Ag Antibody molecules to tim-3 and uses thereof
CN106103488A (zh) * 2014-02-10 2016-11-09 默克专利有限公司 靶向TGFβ抑制
US20170157250A1 (en) * 2014-07-11 2017-06-08 Genmab A/S Antibodies binding axl
CN107001478A (zh) * 2014-10-14 2017-08-01 诺华股份有限公司 针对pd‑l1的抗体分子及其用途
CN107207593A (zh) * 2014-12-09 2017-09-26 雷纳神经科学公司 抗pd‑1抗体及其使用方法
US20180207273A1 (en) * 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US20170355770A1 (en) * 2016-06-13 2017-12-14 Askgene Pharma Inc. PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
WO2018085469A2 (en) * 2016-11-01 2018-05-11 Anaptysbio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
TW201825513A (zh) * 2016-11-29 2018-07-16 美商提薩羅有限公司 針對ｔ細胞免疫球蛋白及黏蛋白３（ｔｉｍ-３）之抗體

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CATHERINE A.等: "Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy", 《ONCOIMMUNOLOGY》, vol. 7, no. 2, pages 1385690 *
董忠谊等: "抗PD-1免疫治疗获得性耐药机制——新的免疫检查点TIM3激活", 《循证医学》, vol. 16, no. 3, pages 135 - 142 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116688115A (zh) * 2022-03-18 2023-09-05 上海齐鲁制药研究中心有限公司 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途
CN116688115B (zh) * 2022-03-18 2024-02-06 上海齐鲁制药研究中心有限公司 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途

Also Published As

Publication number Publication date
CA3117371A1 (en) 2020-05-07
EP3873612A2 (en) 2021-09-08
JP2022505923A (ja) 2022-01-14
WO2020093024A2 (en) 2020-05-07
WO2020093024A3 (en) 2020-06-04
US20220073616A1 (en) 2022-03-10
IL282708A (en) 2021-06-30
AU2019372436A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
TWI839365B (zh) 間皮素及cd137結合分子
EP3277321B1 (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
CN113301961A (zh) 给予抗tim-3抗体的方法
CN113272017A (zh) 抗tim-3抗体
CN114573699A (zh) 滋养层细胞表面抗原2(trop2)特异性抗体
CN112424229A (zh) 结合cd137和ox40的抗体分子
JP2020514290A (ja) 標的ｔｇｆ−β阻害のための投薬計画及び投薬形態
AU2020363041B2 (en) Antibodies against the poliovirus receptor (PVR) and uses thereof
TW201734044A (zh) 抗－ｍｅｔ抗體及其使用方式
CN110382532A (zh) 抗g-csf抗体及其用途
JP7712496B2 (ja) 抗ｃｄ３９抗体及びその使用
JP2025134713A (ja) Ｐｄ１およびｖｅｇｆｒ２二重結合剤
US20230140694A1 (en) Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
CN111973739A (zh) 抗pd-l1单克隆抗体治疗癌症的用途
JP2021523096A (ja) 未治療対象において癌を治療する際に使用するための標的ｔｇｆ−β阻害のための投与計画
WO2023164872A1 (en) Anti-cd39 antibodies and use thereof
WO2023163968A1 (en) Stable formulations of a multivalent vhh based cytotoxic t lymphocyte associated antigen 4 (ctla4) binder binding to human ctla4 and methods of use thereof
HK40059550A (en) Methods of administering anti-tim-3 antibodies
EP3995147A1 (en) Substance and method for treating tumor
CN114025791A (zh) 癌症治疗
HK40058527A (en) Anti-tim-3 antibodies
US20260115137A1 (en) Stable formulations of a multivalent vhh based cytotoxic t lymphocyte associated antigen 4 (ctla4) binder binding to human ctla4 and methods of use thereof
CN113164599B (zh) 抗pd-l1单克隆抗体治疗癌症的用途
HK40113788A (zh) 抗cd39抗体及其用途
EA049949B1 (ru) Лечение рака

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40059550

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210824

WD01 Invention patent application deemed withdrawn after publication